Embedded in everything we do at BioDuro is the reality that the product we help create has the potential to cure patients.
Chairman and Founder
Embedded in everything we do at BioDuro is the reality that the product we help create has the potential to cure patients. It’s that constant reminder that motivates us to transform the way pharmaceuticals are made. From drug substance to drug product, discovery to development, small molecule or biologics, BioDuro’s solutions provide pharmaceutical and biopharmaceutical companies with the quality results they need to help deliver their drugs to patients.
BioDuro takes pride in the enduring partnerships it has created since its inception in 2005. Although we have grown significantly in the past 13 years, we have been able to maintain and develop key partnerships with our pharmaceutical and biotech partners.
We take pride in upholding a culture of scientific excellence. We hold the scientific integrity of our work as our main priority and strive to maintain our high quality to help advance the field through our services. Our scientific staff is organized in a way that upholds these standards, where our young and talented scientists are mentored by the many seasoned experts among us.
We are proud to claim that our discovery division has delivered 20 compounds into the clinical phases of development. Our commitment to efficiency and quality has allowed us to help our clients reach their discovery results.
On average, our solubility enhancement technologies significantly increase solubility of crystalline API, sometimes even up to 150 fold.
In the past 3 years, our development team has formulated solutions that allowed for 25 drugs to reach the clinic.
In 2015, our manufacturing team successfully completed 100% of its cGMP manufacturing campaigns. Adhering to the core principles of flexibility, visibility, and reliability, our growing manufacturing division has made BioDuro a trusted name in the industry.
BioDuro is founded in California with investment from Biotech Investment Group, a San Diego private equity firm. BioDuro begins CRO service operations in Beijing.
BioDuro expands to more than 600 employees in its Beijing facility, and becomes part of PPD’s global CRO services later that year.
BioDuro opens a 92,000 square-foot state-of-the-art lab in Shanghai to meet increasing client demand for DMPK, bioanalytical, chemistry, discovery biology and pharmacology services.
Formex joins the Biotech Investment Group family, operating in a 44,000 square foot formulation development and cGMP manufacturing facility in the Torrey Pines biotech hub of San Diego.
BioDuro is reacquired from PPD. BioDuro and Formex merge to enable service offerings that span from API synthesis to formulation development and cGMP manufacture of drug product.
BioDuro acquires Molecular Response to expand oncology service offering including hTME-3DX Screen and Verify™